Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich Sells 1,998 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36. Following the completion of the sale, the chief operating officer now directly owns 27,015 shares of the company’s stock, valued at approximately $1,156,782.30. This trade represents a 6.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Mirum Pharmaceuticals Price Performance

MIRM traded down $0.06 during trading on Wednesday, hitting $42.00. 305,985 shares of the company traded hands, compared to its average volume of 405,737. The company has a market cap of $2.02 billion, a PE ratio of -20.79 and a beta of 0.98. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $48.89. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The stock’s 50-day simple moving average is $42.80 and its two-hundred day simple moving average is $40.60.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The company had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm’s revenue for the quarter was up 89.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.57) earnings per share. As a group, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several large investors have recently added to or reduced their stakes in MIRM. Bank of New York Mellon Corp boosted its stake in shares of Mirum Pharmaceuticals by 48.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 143,000 shares of the company’s stock worth $4,889,000 after purchasing an additional 46,506 shares during the period. Commonwealth Equity Services LLC lifted its stake in Mirum Pharmaceuticals by 17.1% in the second quarter. Commonwealth Equity Services LLC now owns 14,050 shares of the company’s stock worth $480,000 after purchasing an additional 2,050 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Mirum Pharmaceuticals by 48.5% during the second quarter. Rhumbline Advisers now owns 52,916 shares of the company’s stock valued at $1,809,000 after buying an additional 17,279 shares during the period. Arizona State Retirement System grew its stake in shares of Mirum Pharmaceuticals by 10.6% during the second quarter. Arizona State Retirement System now owns 9,210 shares of the company’s stock valued at $315,000 after buying an additional 883 shares during the last quarter. Finally, Quest Partners LLC raised its holdings in shares of Mirum Pharmaceuticals by 7,513.3% in the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after buying an additional 1,127 shares during the period.

Analysts Set New Price Targets

Several analysts recently commented on MIRM shares. Leerink Partners lifted their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. HC Wainwright reiterated a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Citigroup boosted their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, Robert W. Baird upped their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.